作为抗候选剂的硫胺的设计和开发:基于计算和斑马鱼的验证方法
Anis Nasuha Adzahar1, Nik Nur Farhana Nik Aizan1, Muhammad Alif Mohammad Latif2
1Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia.
ACS omega
|December 1, 2025
概括
研究人员开发了新的硫胺-混合物作为潜在的抗药物 (AED),向GABAA受体. 化合物20在斑马鱼模型中表现出高结合亲和力,稳定性和良好的安全性,表明其对下一代治疗的承诺.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 计算化学计算化学
背景情况:
- 影响全球数百万人,需要更安全,更有效的抗药物 (AED).
- 目前的AED通常具有显著的副作用,推动了对新型治疗策略的需求.
- γ-氨基黄油酸A型 (GABAA) 受体是调节神经元刺激性和控制发作的关键标.
研究的目的:
- 设计和合成新的硫胺 - 化混合物作为潜在的AED候选者.
- 评估合成化合物的药物相似性,ADMET特性和电子特性.
- 评估化合物向GABAA受体的结合亲和力,稳定性,安全性和抗潜力.
主要方法:
- 合成了36种硫胺-化杂交物.
- 计算分析包括密度函数理论 (DFT) 的电子特性和分子对接GABAA受体.
- 分子动力学 (MD) 模拟来评估排名第一的化合物的稳定性.
- 在体内评估使用斑马鱼死亡率测定 (LC50) 和乙 (PTZ) 诱导的模型.
主要成果:
- 合成了硫胺 - 化混合物,并进行了计算分析.
- 化合物19,20和21对GABAA受体表现出高的结合亲和力,表现优于酸 (VPA).
- 化合物20在MD模拟中表现出优越的稳定性,并且在斑马鱼中表现出良好的安全性.
- 所有测试的化合物在PTZ诱导的发作模型中都显示出抗的潜力.
结论:
- 硫胺-化混合物代表了开发新型AED的有希望的支架.
- 化合物20是一种4- ((trifluoromethyl) -sulfonamide-chalcone衍生物,显示出作为GABAA受体的阳性全调节剂的显著潜力.
- 这种综合的计算和实验方法验证了一种可行的策略,用于发现下一代AED,提高有效性和安全性.
相关概念视频
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
611
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
611
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
791
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
791
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K